Ex-AveX­is crew trims staff at Chica­go-area Jaguar Gene Ther­a­py

Af­ter No­var­tis ac­quired AveX­is, ex­ec­u­tives from the lead­ing gene ther­a­py biotech shuf­fled off to form new star­tups look­ing to re­peat their Zol­gens­ma sto­ry for oth­er dis­eases. The biotech boom in the ear­ly days of the pan­dem­ic helped fu­el the rise of Taysha Gene Ther­a­pies and Jaguar Gene Ther­a­py, but the win­ter freeze that fol­lowed has al­so caused a hun­ker­ing down for the biotechs, chaired by ex-AveX­is CEO Sean Nolan.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER